Skip to content

Effect of Skate Skin Extract on Cognitive Function in Adults

Effect of Skate Skin Extract on Cognitive Function in Adults With Subjective Memory Impairment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03849391
Enrollment
100
Registered
2019-02-21
Start date
2019-02-01
Completion date
2020-02-28
Last updated
2020-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjective Memory Impairment

Brief summary

The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Skate Skin extract on cognitive function in adults with subjective memory impairment for 12 weeks.

Detailed description

Previous animal studies have indicated that Skate Skin extract may have the ability to improve cognitive function. Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Skate Skin extract on cognitive function in adults with subjective memory impairment for 12 weeks; the safety of the compound are also evaluate. The Investigators examine chemical and metabolic parameters, and cognitive function at baseline, as well as after 6 and 12 weeks of intervention. One hundred adults were administered either 500 mg of Skate Skin extract or a placebo each day for 12 weeks;

Interventions

DIETARY_SUPPLEMENTSkate group

This group takes 500 mg/day Skate Skin extract for 12 weeks

DIETARY_SUPPLEMENTPlacebo group

This group takes 500 mg/day Placebo for 12 weeks

Sponsors

Pusan National University Yangsan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Global Deterioration Scale (GDS) 2 or 3

Exclusion criteria

* Abnormal liver or renal function (i.e., serum aminotransferase activity \> 3 times of upper limit of reference range and serum creatinine concentrations \> 1.2 mg/dL) * Diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dL) * History of viral hepatitis or cancer * Uncontrolled hypertension * History of serious cardiac disease such as angina or myocardial infarction * History of gastrectomy * History of medication for psychiatric disease * Administration of oriental medicine including herbs within the past 4 weeks

Design outcomes

Primary

MeasureTime frameDescription
Mini-Mental State Examination total scoreChange from Baseline Mini-Mental State Examination total score at 3 monthsChange in Mini-Mental State Examination total score during 3 months

Secondary

MeasureTime frameDescription
Korean instrumental activity of daily living total scoreChange from Baseline Korean instrumental activity of daily living total score at 3 monthsChange in Korean instrumental activity of daily living total score during 3 months
Computerized NeuroCognitive Function test total scoreChange from Baseline Computerized NeuroCognitive Function test total score at 3 monthsChange in Computerized NeuroCognitive Function test total score during 3 months
brain derived neurotrophic factorChange from Baseline brain derived neurotrophic factor level at 3 monthsChange in brain derived neurotrophic factor level during 3 months

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026